Cadrock Pty Ltd, of Australia has raised $5 million in seed financing from an unnamed Chinainvestor to support clinical trials of an investigational triple-antibiotic as a treatment for coronary artery disease (CAD). The theory that CAD is caused by bacterial infection has not been proven, though a British study showed a 36% reduction in Major Cardiac Events following a course of antibiotics. The therapy was developed by Thomas Borody, MD, PhD, who previously developed a triple antibiotic treatment for peptic ulcers.
Source: China Biotoday
